PGAM1 and cancer: Hence, targeting PGAM1, which may limit both glycolysis and its shunts, is considered as a killing-two-birds-with-one-stone strategy for cancer therapy (Chaneton and Gottlieb, 2012a; Hitosugi et al, 2012).